Hydrogels for combination delivery of antineoplastic agents

被引:127
作者
Bouhadir, KH
Alsberg, E
Mooney, DJ
机构
[1] Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Biol Mat Sci, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA
关键词
alginate; controlled release; biodegradable; antineoplastic agents; doxorubicin; methotrexate; mitoxantrone;
D O I
10.1016/S0142-9612(01)00003-5
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The systemic delivery of anticancer agents has been widely investigated during the past decade but localized delivery may offer a safer and more effective delivery approach. We have designed and synthesized a novel hydrogel to locally deliver antineoplastic agents, and demonstrate the different types of release that can be achieved from these hydrogels using three model drugs: methotroxate, doxorubicin, and mitoxantrone. Alginate was chemically modified into low molecular weight oligomers and crosslinked with a biodegradable spacer (adipic dihydrazide) to form biodegradable hydrogels. The model antineoplastic agents were loaded into the hydrogel via three different mechanisms. Methotrexate was incorporated within the pores of the hydrogel and was released by diffusion into the surrounding medium. Doxorubicin was covalently attached to the polymer backbone via a hydrolytically labile linker and was released following the chemical hydrolysis of the linker. Mitoxantrone was ionically complexed. to the polymer and was released after the dissociation of this complex. These three release mechanisms could potentially be used to deliver a wide selection of antineoplastic agents, based on their chemical structure. This novel delivery system allows for the release of single or combinations of antineoplastic agents, and may find utility in localized antineoplastic agent delivery. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2625 / 2633
页数:9
相关论文
共 30 条
[1]   RADIOIODINATION OF ALGINATE VIA COVALENTLY-BOUND TYROSINAMIDE ALLOWS MONITORING OF ITS FATE IN-VIVO [J].
ALSHAMKHANI, A ;
DUNCAN, R .
JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS, 1995, 10 (01) :4-13
[2]   Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer - a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group [J].
Andersson, M ;
Madsen, EL ;
Overgaard, M ;
Rose, C ;
Dombernowsky, P ;
Mouridsen, HT .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (01) :39-46
[3]   New developments in antitumor anthracyclines [J].
Arcamone, F ;
Animati, F ;
Capranico, G ;
Lombardi, P ;
Pratesi, G ;
Manzini, S ;
Supino, R ;
Zunino, F .
PHARMACOLOGY & THERAPEUTICS, 1997, 76 (1-3) :117-124
[4]   DAUNORUBICIN AND DOXORUBICIN, ANTHRACYCLINE ANTIBIOTICS, A PHYSICOCHEMICAL AND BIOLOGICAL REVIEW [J].
AUBELSADRON, G ;
LONDOSGAGLIARDI, D .
BIOCHIMIE, 1984, 66 (05) :333-352
[5]  
Bouhadir KH, 2000, J PHARM SCI-US, V89, P910, DOI 10.1002/1520-6017(200007)89:7<910::AID-JPS8>3.0.CO
[6]  
2-#
[7]   Synthesis of cross-linked poly(aldehyde guluronate) hydrogels [J].
Bouhadir, KH ;
Hausman, DS ;
Mooney, DJ .
POLYMER, 1999, 40 (12) :3575-3584
[8]  
Britten CD, 1999, CANCER RES, V59, P1049
[9]  
Buzdar AU, 1999, SEMIN ONCOL, V26, P21
[10]  
Calabresi P., 1975, PHARMACOL BASIS THER, P1254